OrthoPediatrics Corp. (NASDAQ:KIDS) EVP Gregory A. Odle Sells 1,771 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS – Get Rating) EVP Gregory A. Odle sold 1,771 shares of the business’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $45.00, for a total value of $79,695.00. Following the sale, the executive vice president now owns 73,125 shares of the company’s stock, valued at $3,290,625. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

OrthoPediatrics Price Performance

KIDS stock opened at $44.15 on Wednesday. OrthoPediatrics Corp. has a 1-year low of $35.67 and a 1-year high of $60.75. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 116.18 and a beta of 0.80. The business has a 50 day simple moving average of $41.38 and a two-hundred day simple moving average of $45.18.

OrthoPediatrics (NASDAQ:KIDS – Get Rating) last posted its quarterly earnings results on Monday, October 31st. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.14. OrthoPediatrics had a negative return on equity of 5.60% and a net margin of 7.90%. The business had revenue of $34.95 million during the quarter, compared to the consensus estimate of $36.44 million. Sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on KIDS shares. JMP Securities cut their price objective on OrthoPediatrics from $70.00 to $60.00 and set a “market outperform” rating for the company in a research note on Wednesday, November 2nd. Needham & Company LLC cut their price objective on OrthoPediatrics from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, November 1st. Stifel Nicolaus cut their price objective on OrthoPediatrics from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, January 10th. Truist Financial cut their price objective on OrthoPediatrics from $66.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, October 17th. Finally, Piper Sandler cut their price objective on OrthoPediatrics from $58.00 to $52.00 in a research note on Tuesday, November 1st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $54.33.

Institutional Trading of OrthoPediatrics

Several hedge funds have recently modified their holdings of KIDS. Point72 Hong Kong Ltd purchased a new stake in shares of OrthoPediatrics during the 1st quarter worth approximately $26,000. MCF Advisors LLC purchased a new stake in shares of OrthoPediatrics during the 3rd quarter worth approximately $33,000. Almanack Investment Partners LLC. purchased a new stake in shares of OrthoPediatrics during the 3rd quarter worth approximately $34,000. Lazard Asset Management LLC purchased a new stake in shares of OrthoPediatrics during the 1st quarter worth approximately $65,000. Finally, Harbor Investment Advisory LLC raised its holdings in shares of OrthoPediatrics by 24.3% during the 2nd quarter. Harbor Investment Advisory LLC now owns 1,578 shares of the company’s stock worth $68,000 after acquiring an additional 308 shares in the last quarter. 97.02% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

(Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.